Vertex Pharmaceuticals Inc / Ma (VRTX): who owns it and who trades it
As of Nov 16, 2026, VRTX insiders reported 90 open-market sales worth $140M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jeffrey M Leiden (Chair), with $28.7M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Vertex Pharmaceuticals Inc / Ma
From the latest filingsOverall: about as much buying as selling. Congress mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns VRTX
1,745 funds and institutions reported VRTX shares worth $120B at the end of Q2 2026, about 95% of the company. The largest holder is Capital World Investors with 10.3%.
Funds and institutions (13F) 95%Everyone else 5%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Capital World Investors | 26.12M | 10.29% | $13B | +3% |
| BlackRock, Inc. | 24.11M | 9.50% | $12B | +1% |
| Capital Research Global Investors | 19.49M | 7.68% | $9.7B | -8% |
| Vanguard Capital Management LLC | 16.58M | 6.53% | $8.2B | +0% |
| State Street Corp | 11.87M | 4.68% | $5.9B | +1% |
| Invesco Ltd. | 8.04M | 3.17% | $4B | +214% |
| JPMorgan Chase & Co | 6.52M | 2.57% | $3.3B | – |
| Geode Capital Management, LLC | 6.02M | 2.37% | $3B | -2% |
| Vanguard Portfolio Management LLC | 4.88M | 1.92% | $2.4B | -5% |
| Capital International Investors | 4.70M | 1.85% | $2.3B | -8% |
| Loomis Sayles & Co L P | 3.92M | 1.54% | $1.9B | -2% |
| Franklin Resources Inc | 3.35M | 1.32% | $1.7B | +507% |
| Wellington Management Group LLP | 3.25M | 1.28% | $1.6B | +1% |
| Morgan Stanley | 3.24M | 1.28% | $1.6B | +2% |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 3.09M | 1.22% | $1.5B | +1% |
| Bank of America Corp | 3.04M | 1.20% | $1.5B | +6% |
| Alliancebernstein L.P. | 3.02M | 1.19% | $1.3B | -23% |
| Jennison Associates LLC | 3.00M | 1.18% | $1.5B | +9% |
| Norges Bank | 2.97M | 1.17% | $1.5B | – |
| Ameriprise Financial Inc | 2.60M | 1.03% | $1.3B | -1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, VRTX insiders reported $0 of open-market purchases and $140M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Charles F Wagner Jr | Vice president | Sale plan | 15,286 | $547.87 | $8.4M | Form 4 |
| Nov 6, 2026 | Reshma Kewalramani | CEO | Sale plan | 11,866 | $531.53 | $6.3M | Form 4 |
| Jul 2, 2026 | Ourania Tatsis | Vice president | Sale plan | 1,500 | $524.99 | $787K | Form 4 |
| Jul 2, 2026 | Duncan McKechnie | Vice president | Sale plan | 1,541 | $519.00 | $800K | Form 4 |
| Jul 1, 2026 | Joy Liu | Vice president | Sale plan | 828 | $502.71 | $416K | Form 4 |
| Jun 26, 2026 | Carmen Bozic | Vice president | Sale plan | 596 | $482.50 | $288K | Form 4 |
| Jun 18, 2026 | Carmen Bozic | Vice president | Sale plan | 1,020 | $462.17 | $471K | Form 4 |
| Jun 15, 2026 | Carmen Bozic | Vice president | Sale plan | 4,062 | $450.00 | $1.8M | Form 4 |
| Jun 5, 2026 | Carmen Bozic | Vice president | Sale plan | 1,745 | $450.00 | $785K | Form 4 |
| Jun 1, 2026 | Joy Liu | Vice president | Sale plan | 828 | $439.91 | $364K | Form 4 |
| May 29, 2026 | Carmen Bozic | Vice president | Sale plan | 1,974 | $450.00 | $888K | Form 4 |
| May 15, 2026 | Mark E. Bunnage | Vice president | Sale plan | 33 | $453.45 | $15K | Form 4 |
| May 15, 2026 | Carmen Bozic | Vice president | Sale plan | 1,354 | $453.45 | $614K | Form 4 |
| May 12, 2026 | Carmen Bozic | Vice president | Sale plan | 6,988 | $450.00 | $3.1M | Form 4 |
| May 4, 2026 | Sangeeta N. Bhatia | Director | Sale plan | 318 | $423.73 | $135K | Form 4 |
| May 1, 2026 | Joy Liu | Vice president | Sale plan | 1,104 | $425.02 | $469K | Form 4 |
| Apr 1, 2026 | Joy Liu | Vice president | Sale plan | 978 | $449.17 | $439K | Form 4 |
| Mar 27, 2026 | Carmen Bozic | Vice president | Sale plan | 2,329 | $450.95 | $1.1M | Form 4 |
| Mar 13, 2026 | Carmen Bozic | Vice president | Sale plan | 2,329 | $481.79 | $1.1M | Form 4 |
| Mar 11, 2026 | Duncan McKechnie | Vice president | Sale plan | 2,633 | $498.42 | $1.3M | Form 4 |
| Mar 4, 2026 | Duncan McKechnie | Vice president | Sale plan | 2,437 | $475.30 | $1.2M | Form 4 |
| Mar 2, 2026 | Joy Liu | Vice president | Sale plan | 892 | $495.96 | $442K | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 3,278 | $488.27 | $1.6M | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 2,510 | $487.13 | $1.2M | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 240 | $482.84 | $116K | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 120 | $481.50 | $57.8K | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 400 | $479.75 | $192K | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 460 | $489.32 | $225K | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 1,725 | $496.95 | $857K | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 5,995 | $496.16 | $3M | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 2,725 | $490.54 | $1.3M | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 949 | $491.30 | $466K | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 2,520 | $493.29 | $1.2M | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 3,498 | $494.33 | $1.7M | Form 4 |
| Feb 27, 2026 | Reshma Kewalramani | CEO | Sale plan | 15,580 | $495.38 | $7.7M | Form 4 |
| Feb 27, 2026 | Carmen Bozic | Vice president | Sale plan | 2,329 | $480.31 | $1.1M | Form 4 |
| Feb 26, 2026 | Kristen Ambrose | Vice president | Sale plan | 357 | $483.36 | $173K | Form 4 |
| Feb 25, 2026 | Ourania Tatsis | Vice president | Sale plan | 260 | $486.35 | $126K | Form 4 |
| Feb 25, 2026 | Amit Sachdev | Vice president | Sale plan | 1,846 | $486.35 | $898K | Form 4 |
| Feb 25, 2026 | Duncan McKechnie | Vice president | Sale plan | 2,410 | $489.00 | $1.2M | Form 4 |
| Feb 25, 2026 | Duncan McKechnie | Vice president | Sale plan | 2,500 | $486.35 | $1.2M | Form 4 |
| Feb 25, 2026 | Mark E. Bunnage | Vice president | Sale plan | 620 | $486.35 | $302K | Form 4 |
| Feb 25, 2026 | Jonathan Biller | Vice president | Sale plan | 945 | $486.35 | $460K | Form 4 |
| Feb 25, 2026 | Edward Morrow Atkinson III | Vice president | Sale plan | 668 | $486.35 | $325K | Form 4 |
| Feb 25, 2026 | Kristen Ambrose | Vice president | Sale plan | 223 | $486.35 | $108K | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 2,730 | $465.05 | $1.3M | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 4,237 | $471.43 | $2M | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 920 | $463.91 | $427K | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 1,848 | $465.80 | $861K | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 10,263 | $467.75 | $4.8M | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 19,662 | $468.57 | $9.2M | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 7,241 | $469.61 | $3.4M | Form 4 |
| Feb 19, 2026 | Amit Sachdev | Vice president | Sale plan | 11,712 | $470.54 | $5.5M | Form 4 |
| Feb 18, 2026 | Ourania Tatsis | Vice president | Sale plan | 368 | $473.68 | $174K | Form 4 |
| Feb 18, 2026 | Mark E. Bunnage | Vice president | Sale plan | 1,182 | $473.68 | $560K | Form 4 |
| Feb 18, 2026 | Jonathan Biller | Vice president | Sale plan | 1,244 | $473.68 | $589K | Form 4 |
| Feb 18, 2026 | Edward Morrow Atkinson III | Vice president | Sale plan | 817 | $473.68 | $387K | Form 4 |
| Feb 18, 2026 | Kristen Ambrose | Vice president | Sale plan | 638 | $473.68 | $302K | Form 4 |
| Feb 17, 2026 | Ourania Tatsis | Vice president | Sale plan | 609 | $489.46 | $298K | Form 4 |
| Feb 17, 2026 | Mark E. Bunnage | Vice president | Sale plan | 2,437 | $489.46 | $1.2M | Form 4 |
| Feb 17, 2026 | Jonathan Biller | Vice president | Sale plan | 2,476 | $489.46 | $1.2M | Form 4 |
| Feb 17, 2026 | Edward Morrow Atkinson III | Vice president | Sale plan | 2,031 | $489.46 | $994K | Form 4 |
| Feb 17, 2026 | Kristen Ambrose | Vice president | Sale plan | 1,557 | $489.46 | $762K | Form 4 |
| Feb 13, 2026 | Ourania Tatsis | Vice president | Sale plan | 1,500 | $499.99 | $750K | Form 4 |
| Feb 13, 2026 | Jonathan Biller | Vice president | Sale plan | 988 | $499.00 | $493K | Form 4 |
| Feb 13, 2026 | Sangeeta N. Bhatia | Director | Sale plan | 266 | $500.00 | $133K | Form 4 |
| Feb 11, 2026 | Ourania Tatsis | Vice president | Sale plan | 466 | $460.43 | $215K | Form 4 |
| Feb 11, 2026 | Mark E. Bunnage | Vice president | Sale plan | 2,021 | $460.43 | $931K | Form 4 |
| Feb 11, 2026 | Jonathan Biller | Vice president | Sale plan | 1,925 | $460.43 | $886K | Form 4 |
| Feb 11, 2026 | Edward Morrow Atkinson III | Vice president | Sale plan | 1,751 | $460.43 | $806K | Form 4 |
| Feb 11, 2026 | Kristen Ambrose | Vice president | Sale plan | 1,376 | $460.43 | $634K | Form 4 |
| Jan 7, 2026 | Ourania Tatsis | Vice president | Sale plan | 4,500 | $474.99 | $2.1M | Form 4 |
| Jan 6, 2026 | Charles F Wagner Jr | Vice president | Sale plan | 9,532 | $461.00 | $4.4M | Form 4 |
| Dec 3, 2025 | Charles F Wagner Jr | Vice president | Sale plan | 7,000 | $451.00 | $3.2M | Form 4 |
| Dec 3, 2025 | Charles F Wagner Jr | Vice president | Sale plan | 7,000 | $461.00 | $3.2M | Form 4 |
| Dec 3, 2025 | Ourania Tatsis | Vice president | Sale plan | 4,500 | $449.99 | $2M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 7,899 | $445.56 | $3.5M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 10,360 | $453.34 | $4.7M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 15,681 | $452.20 | $7.1M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 5,809 | $451.20 | $2.6M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 5,880 | $449.84 | $2.6M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 2,320 | $448.78 | $1M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 1,152 | $447.05 | $515K | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 2,070 | $455.22 | $942K | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 4,469 | $440.40 | $2M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 1,320 | $441.26 | $582K | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 2,469 | $443.21 | $1.1M | Form 4 |
| Dec 3, 2025 | Jeffrey M Leiden | Chair | Sale plan | 4,352 | $444.36 | $1.9M | Form 4 |
| Dec 3, 2025 | Jonathan Biller | Vice president | Sale plan | 347 | $449.00 | $156K | Form 4 |
| Nov 17, 2025 | Edward Morrow Atkinson III | Vice president | Sale plan | 2,500 | $434.58 | $1.1M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jeffrey M Leiden | Executive Chairman, Director | – | $28.7M | Dec 3, 2025 |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | – | $28.4M | Feb 25, 2026 |
| Reshma Kewalramani | CEO & President, Director | – | $26M | Nov 6, 2026 |
| Charles F Wagner Jr | EVP, CO & FO | – | $19.2M | Nov 12, 2026 |
| Carmen Bozic | EVP and CMO | – | $11.3M | Jun 26, 2026 |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | – | $6.5M | Jul 2, 2026 |
| Duncan McKechnie | EVP, Chief Commercial Officer | – | $5.7M | Jul 2, 2026 |
| Jonathan Biller | EVP and Chief Legal Officer | – | $3.8M | Feb 25, 2026 |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | – | $3.6M | Feb 25, 2026 |
| Mark E. Bunnage | EVP, Chief Scientific Officer | – | $3M | May 15, 2026 |
| Joy Liu | EVP and Chief Legal Officer | – | $2.1M | Jul 1, 2026 |
| Kristen Ambrose | SVP & Chief Accounting Officer | – | $2M | Feb 26, 2026 |
| Sangeeta N. Bhatia | Director | – | $268K | May 4, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
VRTX short interest
Low short interest. 1.9% of VRTX shares are sold short: about 1 share in 53. Over the last 12 reports the number of shares short went up 8%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 4.81M VRTX shares were sold short, 1.9% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 3.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 4.81M | 1.90% | +13% | 1.42M | 3.4 |
| Oct 15, 2026 | 4.26M | 1.68% | -5% | 1.26M | 3.4 |
| Sep 30, 2026 | 4.50M | 1.78% | -5% | 1.06M | 4.2 |
| Sep 15, 2026 | 4.72M | 1.86% | +1% | 938,157 | 5.0 |
| Aug 31, 2026 | 4.66M | 1.84% | +12% | 1.03M | 4.5 |
| Aug 14, 2026 | 4.15M | 1.64% | +5% | 1.34M | 3.1 |
| Jul 31, 2026 | 3.94M | 1.56% | -21% | 1.32M | 3.0 |
| Jul 15, 2026 | 4.99M | 1.96% | +1% | 1.61M | 3.1 |
| Jun 30, 2026 | 4.94M | 1.95% | +7% | 2.45M | 2.0 |
| Jun 15, 2026 | 4.62M | 1.82% | +3% | 1.21M | 3.8 |
| May 29, 2026 | 4.49M | 1.77% | +1% | 1.41M | 3.2 |
| May 15, 2026 | 4.46M | 1.76% | +7% | 1.22M | 3.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded VRTX
Since Nov 17, 2024, 5 members of Congress reported 5 purchases and 7 sales of VRTX. The latest was a sale by David J. Taylor on Aug 26, 2026, reported Sep 5, 2026.
Purchases 5Sales 7
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | David J. Taylor (R-OH) | Sale | $1K–$15K | Self | Sep 5, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Jan 29, 2026 | David J. Taylor (R-OH) | Sale | $1K–$15K | Self | Feb 2, 2026 | Report |
| Aug 7, 2025 | David J. Taylor (R-OH) | Purchase | $1K–$15K | Self | Sep 2, 2025 | Report |
| Jun 11, 2025 | Lisa C. McClain (R-MI) | Sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| Jun 10, 2025 | Lisa C. McClain (R-MI) | Partial sale | $1K–$15K | Spouse | Aug 13, 2025 | Report |
| May 12, 2025 | Jefferson Shreve (R-IN) | Sale | $15K–$50K | Self | Jun 22, 2025 | Report |
| Mar 20, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Self | Apr 14, 2025 | Report |
| Mar 20, 2025 | Byron Donalds (R-FL) | Sale | $1K–$15K | Spouse | Apr 14, 2025 | Report |
| Mar 13, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Apr 11, 2025 | Report |
| Feb 24, 2025 | Jefferson Shreve (R-IN) | Purchase | $15K–$50K | Self | Mar 9, 2025 | Report |
| Dec 11, 2024 | Lisa C. McClain (R-MI) | Purchase | $1K–$15K | Spouse | Aug 13, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Vertex Pharmaceuticals Inc / Ma company events
Vertex Pharmaceuticals Inc / Ma filed 10 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 2, 2026.
- Nov 2, 2026ResultsReleased financial results. Filing
- Oct 20, 2026LeadershipDeparture of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Sep 1, 2026LeadershipDeparture of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jul 7, 2026AgreementVertex Pharmaceuticals Incorporated, a Massachusetts corporation, Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, and Crinetics Pharmaceuticals, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger. Filing
- May 13, 2026LeadershipThe Board of Directors of Vertex Pharmaceuticals Incorporated approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan, which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval. Filing
- May 4, 2026ResultsReleased financial results. Filing
- Apr 29, 2026LeadershipSuketu Upadhyay informed the board of directors of Vertex Pharmaceuticals Incorporated of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders. Filing
- Mar 31, 2026AnnouncementVertex Pharmaceuticals Incorporated has completed the submission to the U.S. Food and Drug Administration of its rolling Biologics Licensing Application for potential accelerated approval of povetacicept for the treatment of immunoglobulin A nephropathy in adults. Filing
- Feb 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
How Vertex Pharmaceuticals Inc / Ma makes money
Trikafta/Kaftrio brought in 86% of Vertex Pharmaceuticals Inc / Ma's revenue ($10.3B of $12B) in 2025. Alyftrek was next, at 7%.
By product or service, 2025
By region, 2025
From Vertex Pharmaceuticals Inc / Ma's annual report (10-K) for the year ended Dec 31, 2025, filed Feb 13, 2026. The company chooses how to group its revenue, so the parts differ from one company to the next. Read the filing · How the biggest companies make money
Vertex Pharmaceuticals Inc / Ma financials
Famous investors that hold VRTX
5 of the 50 well-known investors we track reported holding VRTX in their latest 13F filing. The largest position is Ken Griffin's, worth $540M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.03M | $540M | 0.3% | +102% |
| Israel Englander · Millennium Management | Q3 2026 | 567,655 | $297M | 0.2% | +21% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 396,768 | $207M | 0.3% | +24% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 34,915 | $18.3M | 0.1% | +221% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 28,676 | $15M | 0.0% | +17% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named VRTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Capital Research Global Investors | 13G/A | 7.0% |
| Nov 13, 2026 | Capital Research Global Investors | 13G/A | 7.0% |
Questions about Vertex Pharmaceuticals Inc / Ma (VRTX) stock
Who owns the most VRTX stock?
The largest reported owner of Vertex Pharmaceuticals Inc / Ma (VRTX) is Capital World Investors, with 10.3% of the company. In total, 1,745 funds and institutions reported holding VRTX at the end of Q2 2026, together about 95% of the shares. See the largest owners.
Are VRTX insiders buying or selling?
In the last 12 months, VRTX insiders reported no open-market purchases and 90 sales worth $140M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in VRTX?
As of Oct 30, 2026, 4.81M VRTX shares were sold short, 1.9% of the shares outstanding, up 12.9% from the report before. At the average daily volume of 1.42M shares, buying them all back would take about 3.4 trading days (days to cover). See the history.
Have members of Congress traded VRTX?
Yes. 5 members of Congress reported 5 purchases and 7 sales of VRTX since Nov 17, 2024. The latest was reported on Sep 5, 2026. See the trades.
How does Vertex Pharmaceuticals Inc / Ma make money?
Trikafta/Kaftrio brought in 86% of Vertex Pharmaceuticals Inc / Ma's revenue ($10.3B of $12B) in 2025. Alyftrek was next, at 7%. See the full split.
Which famous investors hold VRTX?
5 of the 50 well-known investors we track reported VRTX in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $540M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.